Amylin Pharmaceuticals, Inc

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improve the lives of people with metabolic diseases. Amylin’s two first-in-class diabetes product candidates–SYMLIN® and exenatide–are being developed to address the diabetes epidemic. Amylin is developing candidates for diabetes, cardiovascular disease and obesity by utilizing its research with the common metabolic properties.

Activity:

- Research & Development

Product / Technology type(s) covered:

- Pharmaceuticals / Therapeutics

Therapeutic targets:

- Cardiovascular
- Diabetes
- Obesity

Markets Covered

a. HeadQuarter: United States of America

b. Continent(s) active: North America , Europe

c. Countries active: US, Europe

Corporate data:

Number of Employees: 470

Turnover:

Amount:	Year:	Currency:
n/a	2002	US Dollar

Year founded: 1987

Stock options:

	Symbol	Exchange
1	AMLN	NASDAQ

Partners / Alliances: September 2002-Amylin announced a global agreement with Eli Lilly on the development and commercialization of exenatide (synthetic exendin-4). Lilly and Amylin work together in a consensus fashion to co-develop and co-commercialize exenatide.
May 2000-Amylin signed an agreement with Alkermes for the development and manufacturing of an injectable sustained release formulation of exenatide.The goal of this agreement is to develop a sustained release formulation of exenatide for type 2 diabetes.